Source: ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Keishi Sugino, Hirotaka Ono, Hiroshige Shimizu, Takeyuki Kurosawa, Keiko Matsumoto, Masahiro Ando, Kiyoshi Mori, Eiyasu Tsuboi, Sakae Homma, Kazuma Kishi. Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia. ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020

Member's Comments

No comment yet.

Related content which might interest you: The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias Source: Eur Respir Rev 2008; 17: 108-115 Year: 2008 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002 Architectural remodelling in idiopathic interstitial pneumonias: fibrosis or fibroelastosis? Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Idiopathic pulmonary haemosiderosis revisited Source: Eur Respir J 2004; 24: 162-169 Year: 2004 Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia Source: International Congress 2016 – Connective tissue disorders Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Bronchiolitis as a component in idiopathic pulmonary fibrosis and idiopathic interstitial pneumonias: clinico-pathological characteristics Source: Eur Respir J 2004; 24: Suppl. 48, 534s Year: 2004 Clinical significance of histological classification of idiopathic interstitial pneumonia Source: Eur Respir J 2002; 19: 275-283 Year: 2002 Non-IPF idiopathic interstitial pneumonias Source: School Course 2014 - Interstitial lung diseases Year: 2014 Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia Source: Eur Respir J 2002; 19: 1114-1118 Year: 2002 Immunogenetic background of children´s idiopathic interstitial pneumonias and adult idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis Source: International Congress 2016 – Orphan diseases I Year: 2016 Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: 43S-55S Year: 2001